Surface Oncology Future Growth

Future criteria checks 0/6

Surface Oncology is forecast to grow earnings and revenue by 13.8% and 81.8% per annum respectively while EPS is expected to grow by 16.4% per annum.

Key information

13.8%

Earnings growth rate

16.4%

EPS growth rate

Biotechs earnings growth	31.7%
Revenue growth rate	81.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Aug 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:QSOA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	10	-84	N/A	N/A	3
12/31/2024	N/A	-92	N/A	N/A	3
12/31/2023	N/A	-92	N/A	N/A	2
6/30/2023	N/A	-93	-84	-84	N/A
3/31/2023	N/A	-90	-60	-59	N/A
12/31/2022	30	-64	-60	-60	N/A
9/30/2022	30	-66	-54	-54	N/A
6/30/2022	31	-63	-50	-50	N/A
3/31/2022	31	-57	-67	-67	N/A
12/31/2021	3	-78	-62	-62	N/A
9/30/2021	90	13	26	26	N/A
6/30/2021	90	17	31	31	N/A
3/31/2021	89	21	27	27	N/A
12/31/2020	126	59	30	30	N/A
9/30/2020	39	-24	-56	-56	N/A
6/30/2020	39	-25	-60	-60	N/A
3/31/2020	40	-28	-58	-57	N/A
12/31/2019	15	-55	-62	-60	N/A
9/30/2019	25	-44	-63	-61	N/A
6/30/2019	26	-44	-61	-58	N/A
3/31/2019	28	-35	-65	-63	N/A
12/31/2018	59	-7	-15	-13	N/A
9/30/2018	52	-18	-15	-14	N/A
6/30/2018	53	-15	-12	-11	N/A
3/31/2018	57	-13	21	22	N/A
12/31/2017	13	-45	-14	-12	N/A
9/30/2017	12	-36	-13	-11	N/A
12/31/2016	7	-17	N/A	41	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: QSOA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QSOA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QSOA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QSOA is forecast to have no revenue next year.

High Growth Revenue: QSOA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if QSOA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Surface Oncology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies